Welcome to AMYPAD!

We are a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aims to:

Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
AMYPAD publishes new videos
AMYPAD publishes new videos 10 Jan 2019 The past year has been of great progress in AMYPAD, and major milestones were achieved for the DPMS and the PNHS studies......
Recruitment update
Recruitment update 30 Nov 2018 First scan for the AMYPAD PNHS perfomed by VUmc......
Interview with Craig Ritchie
Interview with Craig Ritchie 26 Nov 2018 I am co-leading the Work package 4 “Risk stratification: Natural history and enrichment strategies” with Lisa Ford from Janssen ...
"At this moment, there is a massive effort to better understand the natural history of Alzheimer’s Disease (AD), as well to improve its management. These efforts wish to increase the chances of success for future clinical trials by allowing them to target populations at the early stages of the disease, when the damage could still be reversed. AMYPAD comes to provide valuable insight on a fundamental piece of the AD puzzle: the accumulation of β-amyloid plaques. We will be doing so by determining the role and value of amyloid imaging in disease diagnosis, prognosis, and potential for treatment monitoring - which will be a crucial step forward in the global fight against AD.” Frederik Barkhof
Frederik Barkhof

AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.